Alpha Cognition Inc. ACOG
8.73 USD -0.17 (-1.91%)
At closeNov 10, 2026, 4:00 PM EST
8.73 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
8.50 Day range 8.99
4.50 52-week range 10.14
- YTD
- +34.31%
- 1 year
- +39.46%
- Market cap
- 190.12M
- EPS (ttm)
- -1.32
- YTD return
- +34.31%
- 1-year return
- +39.46%
- Volume
- 107.84K
- Avg volume
- 126.30K
- Open
- 8.74
- Previous close
- 8.90
- Day's range
- 8.50 – 8.99
- 52-week range
- 4.50 – 10.14
5D +0.25 (+2.89%)
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 5.66
- 200-day average
- 5.66
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ACOG Revenue — quarterly 6.09M
ACOG Net income — quarterly -8.79M
ACOG EPS — quarterly -0.40
News
Alpha Cognition Strengthens Its Board of Directors with Appointment of Caren Deardorf 
Alpha Cognition to Participate in Upcoming Investor Events 
Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update 
Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL® 
Alpha Cognition Inc. (NASDAQ:ACOG) Receives Average Recommendation of “Buy” from Brokerages 
Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress 
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Alpha Cognition Announces Data From Its 180-Day Analysis Of Its CONVERGE PRogram For Patients Receiving ZUNVEYL, Donepezil, Galantamine Or Rivastigmine 
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care 
Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI)
Your note
Sign in to keep a note on ACOG — it syncs with the Stock Master app.